[{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vicore Pharma Submits Letter Of Intent For A Clinical Trial Application For A Phase II Study In Patients With COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vicore Pharma BAGS MHRA Nod for Covd-19 Trial in Record Time","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vicore Pharma's Drug Candidate VP01 Demonstrates Potential for Significant Benefit in Severe Pulmonary Hypertension","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vicore Pharma Doses First COVID-19 Patient in the ATTRACT Study in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Robust Effects of VP01 in Human Idiopathic Pulmonary Fibrosis Lung Tissue","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vicore Pharma Recruits the First Patient in the Phase II Proof-of-Concept Study in Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vicore Pharma Reports Positive Top Line Data from the Attract Clinical Study in Patients with Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Results Show that C21 Can Become an Important Complement to COVID-19 Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Data From Phase II study ATTRACT in Patients with COVID-19 Published Online: Vicore Pharma Holding","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vicore Starts Dosing of First COVID-19 Patients in The Global Phase 3 Trial ATTRACT-3","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vicore Obtains SARS Coronavirus Patent for C21 in The USA","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lancet's EClinicalMedicine Publishes Phase 2 Data On C21 in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vicore\u2019s C21 Reduces Long-Term Lung Injury After COVID-19 in the ATTRACT Phase 2 Extension Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vicore's AIR Study Interim Analysis Suggests that C21 Improves Lung Function in IPF Patients","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Emeriti Bio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vicore Takes Major Step Towards a Clinical Platform Company Targeting AT2R \u2013 New Molecule Ready for Phase 1","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vicore announces first human dosed with novel ATRAG, C106","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Orphan Reach","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vicore IPF Interim Data Selected as an Oral \"Late-breaker\" at the ERS Congress","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vicore's Digital Therapeutic For IPF Patients Shows Nearly 50% Anxiety Reduction In Pilot Study","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vicore Initiates Clinical Proof-Of-Concept Study of Endothelial Dysfunction","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I"}]
Find Clinical Drug Pipeline Developments & Deals by Vicore Pharma
C21 is an angiotensin II type 2 receptor agonist, which s being developed for the treatment endothelial dysfunction (reflecting blood vessel health) in patients with type-2-diabetes-mellitus.
C21 is a small molecule compound, which is in clinical development for the treatment of IPF and COVID-19. The experimental programme will assess the potential of C21 for addressing fibrosis, inflammation and vasculopathy in a variety of diseases such as IPF.
The AIR trial1 is an open label single arm phase 2 trial in treatment naïve IPF patients in which 100 mg of C21 (VP01) was administered twice daily for 24 weeks with an optional 12-week extension.
C106 is first of four advanced candidate drugs from VP03 program to enter clinical trials. C106 and the three additional candidates are small molecules with high affinity for AT2R and intended for indications also outside rare lung disease.
The first candidate in the VP03 program, new AT2R agonist C106, shows high selectivity for AT2R and good activity in reducing TGFb in human tissue with patent protection to 2041, is ready to enter a phase 1 trial.
With these results, the company initiates the planning of AIR 2, a double-blind controlled phase 2 dose-finding study to confirm these results and accelerate the development of C21 in parallel to completing the AIR trial.
The results showed nearly 50% reduction in lung injury in the C21 group compared with the placebo group suggest that C21 could accelerate recovery and it is currently being evaluated in a phase 3 trial in COVID-19 patients.
C21 is a first-in-class, orally available, low molecular weight, angiotensin II type 2 receptor (AT2R) agonist that activates the “protective arm” of the renin-angiotensin system (RAS) leading to resolution and regeneration following tissue damage.
C21 is first-in-class, orally available, low molecular weight, angiotensin II type 2 receptor agonist. C21 on respiratory function in COVID-19 was documented in recent phase 2 trial showing that C21 reduced need for supplemental oxygen in hospitalized patients by 90%.
ATTRACT-3 is the pivotal trial in which C21, an angiotensin II type 2 receptor (AT2R) agonist, is tested for the treatment of COVID-19. C21 showed significantly reduced the extended need for supplemental oxygen therapy.
Market Place
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
